Sarepta Therapeutics (SRPT) PT Lowered to $168 at Piper Jaffray on 3Q Report; Lower Projected Enterprise Value Due to 'Eventual Cannibalization by DMD GeneRx'
October 25, 2018 7:54 AM
Piper Jaffray analyst Edward Tenthoff lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
